Home
VectorY

VectorY Market Share Analysis for June 2026

Financing led by founding investor Forbion and a leading global investment firm, and joined by BioGeneration Ventures (BGV) and Eli Lilly & Company Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team Compa

Industry: N/A

Domainvectorytx.com

Year Founded2020

Employees51 - 200

Annual Revenue$2M - $5M

VectorY

VectorY (including company regionals)

vectorytx.com

See more website traffic and engagement information

VectorY Revenue up to June 2026 is 2M - 5M

revenue generated by VectorY top domains

VectorY top domains revenue over 3 years

Revenue for VectorY top domains

vectorytx.com2M - 5M

See more with Sales Intelligence

Total visits to VectorY's top domains

Understand VectorY market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

vectorytx.com4.6K

See more with Sales Intelligence

Avg. visit duration in VectorY's top domains

Analyze VectorY engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

vectorytx.com00:00:10

See more with Sales Intelligence

Avg. pageviews on VectorY's top domains

See how VectorY keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

vectorytx.com1.80

See more with Sales Intelligence

VectorY top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by VectorY

These are the website technologies, by industry, used by VectorY top domains

Advertising (19)

PubMatic

Conversion & Analytics (6)

Google Analytics

Payment & Currencies (4)

Cart Functionality

Tracker (3)

Facebook Pixel

More Technologies

9

See all

News & Signals from VectorY

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsUnlearn partnered with vectorytx.com on Feb 12th '26.SAN FRANCISCO, CA, February 12, 2026 (Newswire.com) - Unlearn, a leader in AI solutions for clinical trials, today announced it is partnering with VectorY Therapeutics, a biotechnology company developing vectorized antibody therapies, to support VectorY's PIONEER-ALS Phase 1/2 clinical study by using digital twins as patient-level external comparators for exploratory data analysis.

Newsvectorytx.com is developing vectorized antibody therapies for three neurodegenerative programs.VectorY Therapeutics partnered with Shape Therapeutics to develop vectorized antibody therapies for three neurodegenerative programs using Shape's engineered AAV5-derived SHP-DB1 capsid, designed for deep-brain penetration and reduced toxicity.

Newsvectorytx.com attended event European Society of Gene & Cell Therapy (ESGCT) Conference on Oct 2nd '25.Amsterdam, the Netherlands, Boston, Massachusetts, and Seattle, Washington - October 2, 2025 - VectorY will be present at the European Society of Gene & Cell Therapy (ESGCT) Conference in Seville on 7 - 10 Oct, 2025.